Themis Medicare Gains 9.25%: Profitability Surge Amid Revenue Challenges

46 minutes ago
share
Share Via
Themis Medicare Ltd delivered a strong weekly performance, rising 9.25% from Rs.100.63 to Rs.109.94, significantly outperforming the Sensex which was virtually flat with a 0.01% gain. The stock’s rally was driven by a sharp rebound in profitability despite ongoing concerns over declining revenue, reflecting a complex but positive financial trend for the micro-cap pharmaceutical firm.

Key Events This Week

May 25: Stock dips 0.74% amid broad Sensex rally

May 26: Sharp 6.37% gain on heavy volume

May 27: Further 6.87% rise as quarterly results approach

May 29: Profitability rebound reported; stock closes down 3.18%

Week Open
Rs.100.63
Week Close
Rs.109.94
+9.25%
Week High
Rs.113.55
vs Sensex
+9.24%

May 25: Initial Weakness Despite Sensex Rally

The week began with Themis Medicare’s stock closing at Rs.99.89, down 0.74% from the previous close of Rs.100.63. This decline contrasted with a strong Sensex gain of 1.23% to 35,849.10, indicating initial investor caution towards the stock amid broader market optimism. The relatively low volume of 5,368 shares suggested subdued trading interest on this day.

May 26: Strong Rebound on Heavy Volume

The stock rebounded sharply, gaining 6.37% to close at Rs.106.25 on significantly higher volume of 14,105 shares. This rise occurred despite the Sensex slipping 0.17% to 35,787.99, highlighting stock-specific buying interest. The surge likely reflected anticipation of upcoming quarterly results and renewed investor confidence in the company’s operational outlook.

May 27: Continued Momentum Ahead of Results

The upward momentum extended with a 6.87% gain to Rs.113.55 on robust volume of 29,112 shares. The Sensex also advanced 0.31% to 35,899.16, but Themis Medicare’s outperformance was notable. The stock’s intraday strength suggested positive sentiment building ahead of the quarterly earnings announcement, with investors positioning for potential upside.

Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?

  • - Building momentum strength
  • - Investor interest growing
  • - Limited time advantage

Join the Momentum →

May 29: Quarterly Results Reveal Profitability Surge Amid Revenue Decline

Themis Medicare reported mixed quarterly results for the period ended March 2026, which had a notable impact on the stock price. The company’s net sales declined by 9.3% to ₹76.53 crores compared to the average of the previous four quarters, signalling ongoing top-line challenges. However, profitability metrics showed a remarkable turnaround.

Profit Before Tax excluding other income (PBT LESS OI) surged 187.5% to ₹5.39 crores, while Profit After Tax (PAT) soared 314.7% to ₹8.89 crores. This sharp increase in PAT was driven in part by non-operating income, which accounted for 40.51% of PBT, indicating margin expansion despite the sales contraction.

Operational concerns remain, with cash and cash equivalents at a low ₹9.15 crores and a declining debtors turnover ratio of 1.92 times, suggesting slower collections and potential working capital inefficiencies. These factors may constrain liquidity and operational flexibility going forward.

The stock closed lower at Rs.109.94, down 3.18% on the day, reflecting some investor caution following the mixed earnings release. The Sensex also declined 1.34% to 35,417.64, indicating a broadly negative market environment on the day.

Considering Themis Medicare Ltd? Wait! SwitchER has found potentially better options in and beyond. Compare this micro-cap with top-rated alternatives now!

  • - Better options discovered
  • - + beyond scope
  • - Top-rated alternatives ready

Compare & Switch Now →

Daily Price Comparison: Themis Medicare vs Sensex

Date Stock Price Day Change Sensex Day Change
2026-05-25 Rs.99.89 -0.74% 35,849.10 +1.23%
2026-05-26 Rs.106.25 +6.37% 35,787.99 -0.17%
2026-05-27 Rs.113.55 +6.87% 35,899.16 +0.31%
2026-05-29 Rs.109.94 -3.18% 35,417.64 -1.34%

Key Takeaways

Themis Medicare’s 9.25% weekly gain significantly outpaced the Sensex’s flat performance, driven largely by a sharp rebound in profitability despite a 9.3% decline in quarterly sales. The company’s ability to expand margins and post a 314.7% increase in PAT highlights operational improvements and the impact of non-operating income, which accounted for over 40% of pre-tax profits.

However, the decline in net sales and liquidity pressures, evidenced by the lowest cash balances in recent periods and a deteriorating debtors turnover ratio, present cautionary signals. These factors could limit the company’s capacity to invest or manage working capital efficiently in the near term.

The stock’s volatility this week, with strong gains midweek followed by a pullback on earnings day, reflects investor uncertainty about the sustainability of the positive financial trend amid revenue challenges. The company’s Mojo Grade remains at 37.0 (Sell), indicating a cautious stance despite recent improvements.

Conclusion

Themis Medicare Ltd’s week was characterised by a notable recovery in profitability that propelled the stock to a 9.25% gain, substantially outperforming the Sensex. The mixed quarterly results underline a complex financial picture: while margin expansion and earnings growth are encouraging, the decline in sales and liquidity constraints temper enthusiasm.

Investors should monitor the company’s ability to sustain earnings quality and address working capital inefficiencies in upcoming quarters. The stock’s micro-cap status and sector volatility warrant a balanced approach, recognising both the progress made and the challenges ahead.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Are Themis Medicare Ltd latest results good or bad?
May 29 2026 07:45 PM IST
share
Share Via
When is the next results date for Themis Medicare Ltd?
May 27 2026 11:17 PM IST
share
Share Via
Themis Medicare Ltd is Rated Sell
May 21 2026 10:10 AM IST
share
Share Via
Themis Medicare Ltd is Rated Sell by MarketsMOJO
May 10 2026 10:10 AM IST
share
Share Via
Themis Medicare Ltd is Rated Sell
Apr 29 2026 10:10 AM IST
share
Share Via